Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in preclinical models. This approach not only inhibited cancer cell migration and invasion but also showed strong potential for safer, more precise lung cancer therapy.